NCT02193360 - Pilot Study of FFP104 Dose Escalation in PBC Subjects | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

May 31, 2015

Primary Completion Date

August 31, 2017

Study Completion Date

December 31, 2017

Conditions

Primary Biliary Cirrhosis

Interventions

DRUG

FFP104

Cohorts receiving multiple weekly or biweekly i.v. doses of FFP104. FFP104 dose levels: 1.0, 2.5 and 5.0 mg/kg. Subjects will be treated for 12 weeks and then followed for safety and efficacy assessments for an additional 12 weeks.

Trial Locations (5)

1100 DD

ACTIVE_NOT_RECRUITING

Amsterdam Medical Center, Amsterdam

Unknown

RECRUITING

Erasmus University Medical Center, Rotterdam

RECRUITING

University Hospital Birmingham, Birmingham

RECRUITING

Royal Free Hospital, London

RECRUITING

Newcastle upon Tyne Hospitals, Newcastle upon Tyne